Floatz logo

Pembrolizumab

Fibrolamellar Carcinoma

Allison O'Neill, MDmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

25 Active assets in the Fibrolamellar Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Children's Oncology Group
Phase 3BB
FLUOROURACILUM
M.D. Anderson Cancer Center
Phase 3BB
Nivolumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2B
Sorafenib
St. Jude Children's Research Hospital
Phase 3B
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2B

View all 37 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →